Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07464028) titled 'Terazosin And Metabolic Energetics in Parkinson's Disease' on March 5.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Single Group Assignment. Primary purpose: Basic Science. Masking: Triple (Participant, Care Provider, Investigator).

Primary Sponsor: Nandakumar Narayanan

Condition: Parkinson's Disease (PD)

Intervention: Drug: Terazosin 5 MG

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: July 1, 2026

Target Sample Size: 120

To know more, visit https://clinicaltrials.gov/study/NCT07464028

Published by HT Digital Content Services with p...